Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, Univer...
Main Authors: | Megna M, Potestio L, Fabbrocini G, Ruggiero A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-07-01
|
Series: | Psoriasis: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/long-term-efficacy-and-safety-of-guselkumab-for-moderate-to-severe-pso-peer-reviewed-fulltext-article-PTT |
Similar Items
-
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
by: Matteo Megna, et al.
Published: (2022-07-01) -
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
by: Matteo Megna, et al.
Published: (2022-02-01) -
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
by: Matteo Megna, et al.
Published: (2022-08-01) -
Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01) -
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023-02-01)